Clinuvel Pharmaceuticals Limited
CLVLYOTCHealthcare● Active
$6.50
$-0.23(-3.39%)
Market Cap$327670200
P/E Ratio—
52W High$9
52W Low$5.98
Clinuvel Pharmaceuticals Limited (CLVLY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLVLY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $95.02M | $88.18M | $78.32M | $65.72M | $47.98M |
| Cost of Revenue | $15.88M | $7.73M | $27.73M | $19.10M | $12.77M |
| Gross Profit | $79.14M | $80.45M | $50.59M | $46.62M | $35.20M |
| Gross Margin %(computed) | 83.29% | 91.23% | 64.59% | 70.93% | 73.38% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $1.27M | $1.23M | $0.55M |
| G&A Expenses | $26.85M | $1.74M | $1.32M | $1.15M | $1.10M |
| Total Operating Expenses | $33.40M | $30.09M | $9.68M | $13.53M | $8.51M |
| Operating Income | $45.73M | $48.01M | $40.91M | $33.08M | $26.70M |
| Operating Margin %(computed) | 48.13% | 54.44% | 52.23% | 50.34% | 55.65% |
| Interest Income | $9.43M | $7.32M | $3.91M | $0.44M | $0.34M |
| Interest Expense | $4.46M | $4.45M | $3.19M | $2.27M | $1.62M |
| Income Before Tax | $51.55M | $50.68M | $45.58M | $34.32M | $25.71M |
| Income Tax Expense | $15.38M | $15.04M | $14.97M | $13.44M | $0.98M |
| Net Income | $36.17M | $35.64M | $30.60M | $20.88M | $24.73M |
| Net Margin %(computed) | 38.07% | 40.41% | 39.08% | 31.77% | 51.54% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.72 | $0.72 | $0.62 | $0.42 | $0.50 |
| Wtd Avg Shares | 50.08M | 49.83M | 49.41M | 49.41M | 49.41M |
| EBITDA | $57.20M | $56.28M | $41.70M | $33.84M | $28.19M |
| EBITDA Margin %(computed) | 60.20% | 63.82% | 53.24% | 51.49% | 58.76% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Clinuvel Pharmaceuticals Limited data
About Clinuvel Pharmaceuticals Limited (CLVLY) Income Statement
Clinuvel Pharmaceuticals Limited (CLVLY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CLVLY reported revenue of $0.10B, gross profit of $0.08B (gross margin 83.29%), and net income of $0.04B — a net profit margin of 38.07%.
Frequently asked questions
CLVLY · 4 questionsClinuvel Pharmaceuticals Limited (CLVLY) reported revenue of $0.10B for 2025, up 7.8% year-over-year.
CLVLY revenueCLVLY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09